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Background: Studies have shown that the natural products of Astragalus membranaceus 
(AM) can effectively interfere with a variety of cancers, but their mechanism of action on 
breast cancer remains unclear. Triple-negative breast cancer (TNBC) is associated with 
a severely poor prognosis due to its invasive phenotype and lack of biomarker-driven-
targeted therapies. In this study, the potential mechanism of the target composition acting 
on TNBC was explored by integrated pharmacological models and in vitro experiments.
Materials and Methods: Based on the Gene Expression Omnibus (GEO) database 
and the relational database of Traditional Chinese Medicines (TCMs), the drug and 
target components were initially screened to construct a common network module, and 
multiattribute analysis was then used to characterize the network and obtain key drug-
target information. Furthermore, network topology analysis was used to characterize the 
betweenness and closeness of key hubs in the network. Molecular docking was used to 
evaluate the affinity between compounds and targets and obtain accurate combination 
models. Finally, in vitro experiments verified the key component targets. The cell counting 
kit-8 (CCK-8) assay, invasion assay, and flow cytometric analysis were used to assess 
cell viability, invasiveness, and apoptosis, respectively, after Astragalus polysaccharides 
(APS) intervention. We also performed western blot analysis of key proteins to probe the 
mechanisms of correlated signaling pathways.
Results: We constructed “compound-target” (339 nodes and 695 edges) and 
“compound-disease” (414 nodes and 6458 edges) networks using interaction data. 
Topology analysis and molecular docking were used as secondary screens to identify 
key hubs of the network. Finally, the key component APS and biomarkers PIK3CG, 
AKT, and BCL2 were identified. The in vitro experimental results confirmed that APS 
can effectively inhibit TNBC cell activity, reduce invasion, promote apoptosis, and then 
counteract TNBC symptoms in a dose-dependent manner, most likely by inhibiting the 
PIK3CG/AKT/BCL2 pathway.
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Conclusion: This study provides a rational approach to discovering compounds with a 
polypharmacology-based therapeutic value. Our data established that APS intervenes 
with TNBC cell invasion, proliferation, and apoptosis via the PIK3CG/AKT/BCL2 pathway 
and could thus offer a promising therapeutic strategy for TNBC.
Keywords: triple-negative breast cancer, Astragalus membranaceus, integrated pharmacology, Astragalus 
polysaccharides, PIK3Cg/AKT/BCl2 pathway
INTRODUCTION
Triple-negative breast cancer (TNBC) accounts for 10–20% 
of all breast tumors and has a higher degree of malignancy 
and a worse prognosis than other breast cancer subtypes 
(Bianchini et al., 2016; Logue et al., 2018). Although research 
has provided insight into its pathogenesis and treatment 
strategies, the incidence and mortality of TNBC remain high 
(Ghoncheh et al., 2016; Viens et al., 2017). The side effects and 
drug resistance of conventional drug therapy seriously limit 
their therapeutic effects on TNBC (Chang et al., 2018; Kim 
et al., 2018a). Therefore, research to determine more effective 
and safer drugs to improve the prognosis and survival of 
TNBC patients is needed.
With arsenicals leading to significant breakthroughs in 
the field of leukemia treatment (Zhu et al., 1997), the unique 
antitumor activity of many natural products has attracted 
increasing attention. Astragalus membranaceus (AM), which 
is rich in flavonoids, saponins, and polysaccharides, has been 
widely used in cancer treatment in recent years (Wang et 
al., 2014; Zhu et al., 2015; Kong et al., 2018). For example, 
quercetin, formononetin, calycosin, etc. have shown broad 
antitumor activity (Gao et al., 2014; Massi et al., 2017; Kim 
et al., 2018b; Rauf et al., 2018). The diverse composition of 
AM is the material basis of its effect; however, this diversity 
also complicates pharmacological research. Although some 
progress has been made in the identification of natural 
compound targets, limitations still exist in studies that are 
based on only known effector proteins and approved drugs, 
such as high late-stage clinical attrition rates, cumbersome 
post hoc deconvolution, and low efficiency and innovativeness 
(Terstappen et al., 2007; Hutchinson and Kirk, 2011; 
Waring et  al., 2015). Therefore, it is necessary to find an 
effective innovative measure to elucidate the multiple target 
mechanisms of natural compounds and thus better understand 
their phenotypic effects.
The “integrated pharmacology” (IP) method derived from 
traditional research is becoming increasingly popular (Li et al., 
2018b; Tabrizi et al., 2018). IP aims to find active substances 
that can intervene in underlying impaired mechanisms and 
deregulated interactions by modulating the activity of several 
hubs or by targeting multiple pathways in complex disease 
networks (Kitano, 2007). There is great potential to address 
initial hypotheses for both in vitro and in vivo target validation 
studies that rely on computational methods. In particular, with 
innovation in microarray technologies and the construction of 
public repositories of microarray data, the characterization of 
transcriptome profiles may change at an unprecedented ways 
(Butte, 2002; Lu et al., 2009). Pharmacological research has also 
been improved unprecedentedly with the assistance of computer 
technology (Xu et al., 2017). The development of network 
pharmacology would enable effective elucidating of not yet 
explored natural products, hence providing systematic methods 
to extend the druggable space in various complex diseases 
(Kibble et al., 2015). By the network construction and analysis 
of multiobjective active components and key targets, interactions 
between drugs and specific nodes or modules can be elucidated 
to better identify potential mechanisms.
To explore the possible and novel interference mechanisms of 
AM in TNBC, we constructed a new IP model. This model combines 
microarray data, pharmacokinetic screening, multilevel network 
construction, and in vitro experiments. The scheme for the model 
is shown in Figure 1. We propose that Astragalus polysaccharides 
(APS) could target the PIK3CG/AKT/BCL2 signaling pathway and 
then influence TNBC. This study provides a rational way to screen 
effective compounds and targets, which enhances our ability to 
identify active molecules intervene complex disease.
MATeRIAls AND MeThODs
Differentially expressed gene search, 
Identification, and Analysis
We downloaded the microarray data GSE38959, GSE65194, 
and GSE76275 from the Gene Expression Omnibus (GEO) 
database (http://www.ncbi.nlm.nih.gov/geo/) using their 
microarray platform as GPL4133 and GPL570 (Affymetrix 
Human Gene Expression Array). GSE38959 aims to compare 
gene expression changes between TNBC and normal 
mammary ductal tissues, while the latter two datasets focus 
on comparing TNBC with hormone receptor-positive breast 
cancer. Their intersection can be considered as unique 
biomarkers of TNBC. Differentially expressed genes (DEGs) 
were screened using the online tool GEO2R/R package limma. 
Limma package can fit a linear model for the expression of 
each gene and then carry out residual analysis to obtain the 
appropriate t statistics, which makes the analysis results more 
reliable. In the present study, P < 0.05 and |log2 fold change 
(FC)| > 1 were set as the cut-off criteria between three groups. 
Venn diagrams were used to further calculate the intersection 
of DEGs from two GEO microarray datasets. The heatmap 
of overlapping DEGs was obtained after subtracting Pearson 
correlation clustering using online Morpheus software 
(https://software.broadinstitute.org/morpheus).
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Database Construction and ADMe 
screening of AM
All the ingredients of AM were manually collected from the 
Traditional Chinese Medicine Systems Pharmacology Database 
(TCMSP, http://ibts.hkbu.edu.hk/LSP/tcmsp.php) and TCM 
Database@Taiwan (http://tcm.cmu.edu.tw/). An in silico integrative 
model, ADME (absorption, distribution, metabolism, and 
excretion), was used to predict the pharmacokinetic behaviors 
of chemical compounds. In this process, three ADME-related 
models, including oral bioavailability (OB), Caco-2 permeability, 
and drug likeness (DL), were employed to identify the bioactive 
compounds with favorable pharmacokinetic properties. As 
one of the most vital pharmacokinetic parameters of orally 
administered drugs, OB plays a key role in the efficiencies of 
bioactive compounds in systemic circulation (Saghir, 2009; Tian 
et al., 2011; Xu et al., 2012). The Caco-2 cell model was used as 
a standard in vitro screening tool for predicting intestinal drug 
absorption and drug transport mechanisms. Drug likeness is 
a qualitative profile used in drug design for how “drug-like” a 
substance is with respect to factors such as bioavailability. The 
DL of compounds in AM was assessed based on molecular 
descriptors and the Tanimoto coefficient (Ru et al., 2014),
 
T A B A B
A B A B
,( ) = ∗
+ − ∗2 2  
where A represents any ingredient descriptor of AM, and B is 
the average of this characteristic over all molecules in the DrugBank 
database. In this study, the ingredients meeting the criteria of OB ≥ 
30%, Caco-2 > −0.4, and DL ≥ 0.18 were chosen for further research. 
In addition, we manually retrieved articles published by PubMed 
(https://www.ncbi.nlm.nih.gov/pubmed). In this step, we searched 
the PubMed database with Astragalus propinquus as the subject 
(mesh word) and A. membranaceus and Astragalus mongholicus 
as free words. The search strategy was set as {[(A. membranaceus) 
OR A. mongholicus)] OR “A. propinquus”[Mesh]}. Further, we 
manually screened the articles and incorporated the components 
that were significant and clearly identified in previous studies.
FIgURe 1 | Scheme for the integrated pharmacology approach.
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Identification of Associated  
Compound Targets
Protein information for active ingredients was obtained by using 
the Traditional Chinese Medicine Systems Pharmacology (TCMSP) 
database (http://lsp.nwu.edu.cn/tcmsp.php), SwissTargetPrediction 
(http://www.swisstargetprediction.ch/), and the PharmMapper 
database (http://lilab.ecust.edu.cn/pharmmapper/index.php), which 
all predict interactions between compounds and target proteins 
through structural fitness and previous studies. The SMILES of 
each component was obtained from PubChem (http://pubchem.
ncbi.nlm.nih.gov) and then imported into SwissTargetPrediction. 
Additionally, after the molecular structure was obtained from 
PubChem, it was transformed into Open Bable and saved as a “mol2” 
file, which is suitable for PharmMapper. Accurate information on 
genes and proteins was further extracted from UniProtKB (http://
www.uniprot.org/), which is a protein database with abundant and 
consistent annotation.
Protein–Protein Interaction Network 
Construction and Analysis
We attempted to characterize the multicomponent treatment 
features of AM and to explore the biological effects of small 
molecular compounds. Two networks, including the “compound-
target” network of AM and the “compound-disease” network, 
were constructed using the STRING database (https://string-db.
org/). Interaction data were further read in Cytoscape software 
for visualization and bioinformatics analysis. Gene Ontology 
(GO) and pathway enrichment analyses were based on the 
ClueGO plugin and DAVID database (https://david.ncifcrf.
gov/) to facilitate the biological interpretations. Finally, we 
used the CentiScaPe plug-in to implement topological attribute 
analysis and represent the key hubs in the network based on the 
connectivity of each node.
Molecular Dynamic simulation Docking 
and Target Fishing
To investigate the interaction relationship and mechanisms of 
action between candidate compounds and targets in depth, we 
conducted a molecular dynamics study (molecular docking and 
simulation score) of the two based on the Surflex-docking module 
in SYBYL. It creates a prototype molecule with a representative 
protein activity docking pocket and uses hydrogen bond donors, 
receptors, and water molecules to populate the protein docking 
pockets. SYBYL is also known for its high-accuracy docking, 
high true-positive rate, and fast speed. Before docking, the X-ray 
crystal structures of DEGs were extracted from the RCSB Protein 
Data Bank (http://www.rcsb.org/). Then, they were imported 
into SYBYL to remove cocrystallized ligand and structural water 
molecules and adjunct polar hydrogen atoms. Ligand preparation 
was based on ChemDraw Ultra 8.0 software, which was used 
to construct two-dimensional structures that were saved in 
the mol2 format. Receptor and ligand molecular docking was 
assessed based on the Surflex-docking module. The active pocket 
was obtained based on the ligand mode, and the default values 
for the ProtoMol bloat and ProtoMol threshold parameters were 
set as 0 and 0.50 Å, respectively. Hydrogen bond strength and 
domain structure similarity were used to evaluate the stability 
and reliability of docking. The differential expression of key genes 
in different tissues was characterized by the Gene Expression 
Profiling Interactive Analysis (GEPIA) database (http://gepia.
cancer-pku.cn). We used log2 (TPM + 1) for log-scale, and the jitter 
size was set to 0.4.
Cell Culture
The human TNBC cell line MDA-MB-231 (estrogen receptor 
negative, progesterone receptor negative, and human epidermal 
growth factor receptor-2 negative) was obtained from iCell 
Bioscience Inc. (Shanghai, China) and grown in Dulbecco’s 
Modified Eagle’s Medium (Invitrogen, Carlsbad, CA, USA) 
supplemented with 10% fetal bovine serum (FBS, Gibco, 
Gaithersburg, MD, USA) and 1% penicillin/streptomycin 
(Gibco). All cells were grown as monolayers and maintained in a 
cell culture incubator at 37°C and 5% CO2.
Cell Viability Assay
The cell counting kit-8 (CCK-8, Dojindo, Kumamoto, Japan) 
colorimetric assay was performed to assess cell proliferation. 
MDA-MB-231 cells were seeded (1×103 cells/well) into 96-well 
microplates and allowed to adhere overnight. A total of three 
repeat wells were seeded for each group. The medium was 
removed the following day, and fresh medium with APS (98% 
purity, Yingxin Laboratory, Shanghai, China) (0, 0.25, 0.5, 1, 
or 2 mg/ml) was added. Ten microliters of CCK-8 reagent was 
added to each well at the indicated time points (1, 2, 3, and 4 days 
after seeding into plates), and the mixture was incubated for an 
additional 2 h. The absorbance was measured using a Benchmark 
Microplate Reader (Bio-Rad Laboratories, Hercules, CA, USA) 
at 450 nm.
Invasion Assay
Serum-free cell culture medium was added to the upper chamber 
of a 24-well transwell plate, and the cell density was adjusted to 
1 × 104 cells/ml. MDA-MB-231 cells (100 μl) were seeded into the 
upper chamber of the Transwell migration chamber and incubated 
with different concentrations of APS (0, 0.25, 0.5 mg/ml) for 24 h. 
The cells were fixed with methanol for 20 min and stained 
with 0.1% crystal violet for 5 min, the chamber was then 
placed under an inverted microscope, and the remaining cells 
were counted.
Apoptosis Assay
Apoptosis was evaluated using an Annexin-V fluorescein 
isothiocyanate (FITC) Apoptosis Kit (Solarbio Life Sciences, 
Beijing, China) according to the manufacturer’s protocol. 
Briefly, cells were treated with 1 mg/ml APS for 72 hours. 
Next, 2.0 ml of annexin V-FITC stain and 10 ml of propidium 
iodide (PI) stain were added to 500 μl of binding buffer and 
mixed, which is followed by incubation at room temperature 
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in the dark for 15  min. Finally, apoptosis was evaluated by 
flow cytometry.
Western Blot Assays
First, MDA-MB-231 cells were treated in triplicate with 
or without APS at concentrations of 0.25 and 0.5 mg/ml 
for 48 h. Then, cells were lysed on ice with mixed RIPA 
buffer containing 150 mM NaCl, 1% Triton X-100, 5 mM 
ethylenediaminetetraacetic acid, 10 mM NaF, 1×protease 
inhibitors, and PMSF (Invitrogen, Carlsbad, CA, USA). 
Proteins (30 μg) were loaded onto an SDS-polyacrylamide gel 
electrophoresis (PAGE) gel and transferred to a nitrocellulose 
membrane (Millipore, Bedford, MA). The membrane was 
blocked with 5% nonfat milk for 1 h at room temperature 
and incubated with primary antibodies against PIK3CG, 
AKT, p-AKT, and BCL2 (1:1000, Cell Signaling Technology, 
Inc. Beverly, MA, USA) overnight at 4°C. The next day, after 
washing with cold TBST, the membranes were incubated with 
appropriate horseradish peroxidase-conjugated secondary 
antibodies for 1 h at room temperature. Finally, the bands 
were visualized with the ChemiDoc XRS System (Bio-Rad, 
Hercules, CA, USA).
statistical Analysis
Data are expressed as the mean ± standard deviation of at least 
three independent experiments. Quantitative analysis of figures 
was carried out using the GraphPad Prism 6.0 statistical software 
package (GraphPad Software Inc., La Jolla, CA). The significance 
of multiple comparisons was determined by one-way analysis of 
variance (ANOVA) with SPSS, version 13.0 (SPSS, Inc., Chicago, 
IL, USA). P < 0.05 was considered to indicate a statistically 
significant difference.
ResUlTs
Deg Identification
Microarray expression data, no. GSE38959, no. GSE65194, 
and no. GSE76275, were obtained from the GEO database and 
reanalyzed. We focused on coexpression analysis of DEGs, which 
FIgURe 2 | DEGs between TNBC were identified by three transcription 
profile datasets (GSE38959, GSE65194, GSE76275). DEGs were identified 
with the classical t test, and statistically significant DEGs were defined using 
P < 0.05 and |log2 fold change (FC)| > 1 as the cutoff criteria.
FIgURe 3 | Heatmap plot of the top 50 DEGs between tumors and normal 
tissues. The heatmap was obtained after subtracting Pearson correlation 
clustering, where red represents higher gene expression levels, and blue 
represents lower gene expression levels.
Frontiers in Pharmacology | www.frontiersin.org October 2019 | Volume 10 | Article 1171
APS Interfere With TNBCLiu et al.
6
is more sensitive for identifying treatment-induced deregulation 
among interacting genes. A Venn diagram showed the overlap 
of a total of 229 significant targets (Figure 2). The heatmap was 
structured after clustering the top 50 overlapping DEGs with the 
highest |log2FC| values (Figure 3). The results showed a significant 
difference in the DEG expression among the three samples.
screening for Active Compounds and 
Relevant Targets
Because of the multicomponent characteristics of herbal 
medicines, it is critical to select drugs with satisfactory 
pharmacokinetic properties for further research. A total of 87 
compounds from AM were obtained from the TCMSP database, 
FIgURe 5 | Enrichment of KEGG pathways (A) and gene ontology biological process terms (B) for DEGs. P < 0.05 and false discovery rate (FDR) < 0.05 were set 
as the cutoff criteria; the top 15 meaningful terms are presented in the bubble chart.
FIgURe 4 | Compound-target network and compound-disease network constructed by STRING and Cytoscape. (A) Compound-target network: the blue rectangles 
represent the small molecular component in AM, and the numbers in the rectangles depict the PubChem IDs. The pink circles represent the relevant targets.  
(B) Compound-disease network: as the color deepens and the circle increases, the connectivity of the targets is greater, and the degree of criticality is higher.
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and 16 active components were selected based on the ADME 
model. Further, a total of 1,088 studies related to Astragalus 
were found through literature search. After careful screening, 
we found that, in addition to the 16 compounds screened by 
the ADME model, APS (192 studies) and astragaloside IV 
(170 studies) appeared most frequently. And both of them 
showed real and extensive biological activity in previous 
studies. Thus, 18 active compounds of AM were ultimately 
chosen for further investigation, detailed data was listed in 
Table S1. Compound-related genes were obtained from the 
TCMSP, SwissTargetPrediction, and PharmMapper databases, 
and the remaining 310 genes were obtained after deletion of 
duplicates; raw data and final results were shown in Tables S2 
and S3, respectively. Their official names were obtained from 
the UniProtKB database and used to build networks for further 
characterization of biological characteristics.
Network Construction and Preliminary 
screening of Key Targets
Bioactive natural compounds can regulate a network by 
binding multiple hubs, which implies that they are multi-
targeted when intervening diseases. Hence, to predict 
the target information for the active constituents of AM, 
two networks, “compound-target” (C-T) (Figure 4A) and 
“compound-disease” (C-D) (Figure 4B), were constructed to 
analyze the mechanism.
The C-T network consisted of 339 nodes and 695 edges in 
total. Pathway enrichment (Figure 5A) analysis and GO analysis 
(Figure 5B) were further performed to clarify the biological 
functions of major natural compounds of AM. The results showed 
that the most representative GO biological process (BP) terms 
centered on the “regulation of cell proliferation,” “regulation of 
FIgURe 6 | Topological attribute analysis diagram of the compound-disease 
network. CentiScaPe plug-in in Cytoscape was used to read network data 
and performed topology analysis based on connectivity between nodes.  
The horizontal axis represents betweenness, and the ordinate represents  
the connectivity degree. The graphic in the table represents each target in  
the network.
TABle 1 | Key genes obtained by topological attribute analysis.
ID gene Degree Betweenness Closeness
1 TP53 190 17637.654 0.57032967
2 AKT1 180 14043.39 0.57411504
3 SRC 166 13610.389 0.55212766
4 JUN 155 12211.12 0.5672131
5 VEGFA 150 9618.002 0.5372671
6 IL6 150 9021.176 0.5492064
7 PIK3CG 147 8239.002 0.5356037
8 MAPK1 144 8187.938 0.54516804
9 MYC 140 7663.9834 0.5317623
10 TNF 139 7466.6 0.53450054
11 ESR1 137 7331.85 0.5328542
12 EGF 137 7313.31 0.536157
13 EGFR 135 7259.8237 0.5400624
14 BCL2 133 6536.154 0.5123396
15 FOS 123 6301.0967 0.51744765
FIgURe 7 | Binding interactions of APS with receptors. (A) Structural 
Formula of APS,(B) AKT (PDB ID: 3QKK; score: 4.9589), (C) BCL2 (PDB ID: 
4AQ3; score: 4.4951), and (D) PIK3CG (PDB ID: 2CHX; score: 5.0091). The 
molecules are present as ball and stick models. The dotted yellow lines in 
these pictures represent H-bonds with distance units of Å.
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apoptosis,” “regulation of programmed cell death,” “regulation of 
cell death,” “negative regulation of apoptosis,” “negative regulation 
of programmed cell death,” “negative regulation of cell death,” 
and “positive regulation of cell proliferation,” which indicate the 
well-documented pharmacological and biological effects on cell 
proliferation and apoptosis. Additionally, the enriched pathways 
included the “p53 signaling pathway,” “toll-like receptor signaling 
pathway,” “MAPK signaling pathway,” “apoptosis,” “VEGF 
signaling pathway,” and a variety of tumor-related pathways, 
such as “prostate cancer,” “bladder cancer,” “pancreatic cancer,” 
and “small cell lung cancer.” This result comprehensively shows 
that AM has good antitumor activity and validates the reliability 
of the prediction target.
Topology attribute analysis describes the characteristics 
of the C-D network (414 nodes and 6,458 edges) based on 
degree and betweenness (Figure 6). The results showed that, 
with a higher connectivity of nodes in the network, there were 
fewer corresponding nodes. The cutoff value was set to twice 
the median degree, and 15 key genes based on this value were 
obtained (Table 1).
Docking Combination screen
The Surflex-docking score is based on the binding affinity and 
hydrogen bond strength between ligands and proteins (Ai et al., 
2015). By docking interrelated natural compounds and proteins, 
we discovered good docking results between the high potential 
compound APS (Figure 7A) and the proteins AKT (PDB ID: 
3QKK; score: 4.9589), BCL2 (PDB ID: 4AQ3; score: 4.4951), 
and PIK3CG (PDB ID: 2CHX; score: 5.0091) (Figures 7B–D). 
The differential expression of the three key genes was further 
displayed by boxplots based on the GEPIA database (Figure 8). 
These data provide theoretical evidence that APS in AM may 
play an important role in regulating TNBC. Due to the typical 
enrichment of PIK3CG, AKT, and BCL2 in the classical PI3K/
FIgURe 8 | PIK3CG (A), AKT (B), and BCL2 (C) expression was upregulated in breast tumors compared with that in normal mammary tissues based on TCGA 
data. The total sample was 1,376, of which the number of tumor samples and normal samples were 1,085 and 291, respectively. The jitter size was set as 0.4, and 
we used log2 (TPM + 1) for log-scale.
FIgURe 9 | APS inhibits TNBC cell growth and invasion in vitro. (A) The 
optical density at the indicated concentrations of APS in MDA-MB-231 cells 
was detected by the CCK-8 assay. (B–C) Cells were cultured in triplicate with 
the indicated concentrations of APS for 24 h. The invaded cells were stained 
with crystal violet and counted under a light microscope. *p < 0.05, **p < 
0.01 (compared with the 0 mg/ml group).
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AKT pathway, further in vitro experiments will expand our 
knowledge of PIK3CG/AKT/BCL2.
APs Inhibits the growth and Invasion of 
TNBC Cells
Antiproliferative effects were assessed by CCK-8 assays. 
Briefly, MDA-MB-231 cells were incubated with different 
concentrations of APS for 24, 48, 72, and 96 h; the 
concentrations were set to 0, 0.25, 0.5, 1, and 2 mg/ml, 
respectively. The results showed that the proliferation 
inhibition was concentration-dependent (Figure 9A). TNBC 
cells treated at a concentration of 2 mg/ml showed inhibited 
proliferation at 48 h. When cultured for 72 hours, this 
condition also began to appear in the 1 mg/ml dose group. 
The possibility of whether APS could inhibit the invasive 
ability of TNBC cells was also explored. After the cells were 
cultured with different concentrations of drug (0, 0.25, 0.5 
mg/ml) for 24 h, the invasion ability of MDA-MB-231 cells 
showed varying degrees of decline that were concentration-
independent (Figures 9B, C).
FIgURe 11 | Treatment with APS suppresses the expression levels of PIK3CG/AKT/BCL2-related proteins in MDA-MB-231 cells. Cells were treated in triplicate with 
or without the indicated concentrations of APS. Then, the protein levels of PIK3CG (A–B), AKT, p-AKT (C–D), and BCL2 (e–F) were determined by western blot; 
β-actin was used as an internal control. Data are expressed as the mean ± SD of each group from three separate experiments. **p <0.01 vs. control (0 mg/ml).
FIgURe 10 | Flow cytometry was used to analyze apoptosis of MDA-MB-231 cells treated with APS. (A–B): Control group and 1 mg/ml dose group. (C) The bar 
graphs represent the quantitative analysis of apoptotic cells. *p < 0.05.
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effects of APs on BC Cell Apoptosis
We also investigated whether the suppression of cell growth by 
APS was due to an impact on cell apoptosis. The apoptosis of 
MDA-MB-231 cells was measured by flow cytometry. APS was 
found to affect late apoptosis at a dose of 1 mg/ml; however, 
the rate of early apoptosis appeared relatively unaffected 
(Figure 10).
effect of APs On Protein expression In 
TNBC Cells
As illustrated in Figure 11, the proteins associated with cell cycle 
apoptosis were expressed and detected in the TNBC cell lines 
by immunoblotting. The key targets PIK3CG, AKT, and BCL2 
obtained in this study are closely related to apoptosis. Among 
them, PIK3CG and AKT are essential regulators of apoptosis, 
while BCL2 is a key antiapoptotic protein. Therefore, this study 
aimed to determine whether the apoptotic signaling pathway 
PIK3CG/AKT/BCL2 is directly affected by APS. The results 
suggested that APS decreases the expression levels of PIK3CG 
(Figures 11A, B) and BCL2 (Figures 11E, F) as the concentration 
of APS increases. Although there were no significant inhibitory 
effects on the AKT protein, p-AKT (Figures 11C, D) expression 
was significantly downregulated.
DIsCUssION
TNBC etiologies manifest as a complex disorganized system 
(Barabasi et al., 2011), and accumulating evidence has shown 
that such diseases may not effectively respond to single 
therapeutic interventions. IP provides hypotheses for the 
discovery of key compounds and the exploration of their 
underlying multitarget mechanisms. The study described 
herein highlights how this approach could provide researchers 
with completely unintuitive hypotheses for mechanisms of 
action, thus potentiating innovative findings. Additionally, 
our case study adds evidence that this method is particularly 
effective for research on natural products, which are typically 
multitargeted (Kibble et al., 2015). Here, using IP methods, 
we developed hypotheses for the effect of the natural product 
AM on TNBC. A dual CT and CD network was constructed 
based on the data we excavated, and pathway enrichment and 
GO BP analyses showed the extensive antitumor activity of 
effective AM components. The key hub obtained by topology 
attribute analysis of the network may involve the “drug-
target” interaction. Based on the survival analysis of multiple 
databases and molecular docking, we found the multitargeted 
intervention of APS, the active ingredient in AM.
Previous studies have shown that APS have many biological 
activities, including anti-inflammatory, antioxidant, and 
immunoregulatory properties (Pu et al., 2016; Lv et al., 
2017; Zhou et al., 2017; Zhao et al., 2018). Recently, studies 
have focused on the antitumor activity of APS. Research 
has shown that APS can effectively reduce cell viability and 
induce apoptosis in hepatocellular carcinoma (HCC) cells 
(Huang et al., 2016). APS can also effectively interfere with 
the autophagy pathway to exert antitumor activity (Zhai et al., 
2018). Moreover, the synergistic effect of APS with various 
chemotherapeutic agents, such as cisplatin and doxorubicin 
(Li et al., 2008; Kuo et al., 2015; Li et al., 2018a), has also been 
discovered. Taken together, these studies have shown that 
APS does have an intervention effect on human solid tumors. 
However, its effect on the progression of TNBC as well as 
the underlying regulatory mechanism remains unclear. In 
our study, MDA-MB-231 cells were used to study the effects 
of APS on TNBC cells. The results showed a particularly 
significant intervention activity after APS was applied to 
TNBC cells, especially at the level of apoptosis. This result is 
consistent with the widespread enrichment of GO BPs in the 
“regulation of cell proliferation,” “regulation of cell death,” and 
“regulation of apoptosis.” Furthermore, based on the analysis 
of the drug-target synergy network by IP, APS might regulate 
TNBC by interfering with the PIK3CG/AKT/BCL2 pathway.
Bioinformatics analysis in our study indicates that the 
expression of PIK3CG, AKT, and BCL2 in TNBC tissues is 
significantly higher than that in adjacent healthy tissues 
and in hormone receptor-positive breast tumor tissues. The 
PIK3CG/AKT/BCL2 pathway plays a key role in the regulation 
of apoptosis in cells. Among these proteins, PIK3CG and AKT 
are necessary regulators required for cellular apoptosis. The 
balance between antiapoptotic proteins (such as BCL2) and 
proapoptotic proteins affects tumorigenesis and development 
(Adams and Cory, 2007). Furthermore, molecular docking 
analysis suggested a good structure fit between APS and the 
three proteins. Apoptosis is essential for the morphogenesis, 
development, and homeostasis of multicellular organisms 
(Majtnerova and Rousar, 2018). Focusing on apoptotic 
pathways or hubs and disorders caused by inappropriate 
apoptosis can be a suitable entry point for the treatment 
of many abnormalities, especially for tumors (Fathi et  al., 
2018). The experimental results indeed showed that APS 
at a concentration of 1 mg/ml can effectively promote 
late apoptosis.
PIK3CG, as a member of the class-I catalytic isoforms 
of PI3K (Engelman et al., 2006), is a conspicuous target 
molecule for the regulation of cell survival via PI3K pathways 
and appears to dynamically vary with the expression of PI3K 
(Kachele et al., 2015). Its illegitimate activation has been 
proven to be associated with a variety of cancers (Gorlov 
et al., 2018; Shu et al., 2018; Zhang et al., 2018). Over the past 
decade, the PI3K signaling pathway has been proven to be 
one of the most highly mutated systems in human cancers, 
underscoring its central role in human carcinogenesis 
(Zhang et al., 2017). The intracellular signaling cascades 
initiated by or intersecting PI3K are intricate; the most 
classic of which is the PI3K/AKT signaling pathway. AKT, 
a serine-threonine kinase downstream of PI3K, is regulated 
by PI3K. Its overactivation has been proven to stimulate 
cell cycle progression and promote cell metabolism and 
invasion resistance (Vivanco and Sawyers, 2002; Carnero et 
al., 2008). Several subcellular processes mediated by AKT 
were achieved by phosphorylating different target proteins, 
including intervention in the BCL2 family. The antiapoptotic 
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BCL2 protein family is often dysregulated in human cancers 
by a variety of mechanisms. In the process of tumorigenesis 
and cancer development, cancer cells show dependence on 
upregulation of the antiapoptotic BCL2 protein family and 
tend to induce these survival mechanisms (Certo et al., 2006; 
Juin et al., 2013). Due to their importance in disease biology, 
especially cancers, the regulatory mechanisms of antiapoptotic 
BCL2 family members are being extensively studied (Cui and 
Placzek, 2018). Interestingly, it has been shown that the BCL2 
proapoptotic family contributes to the survival-promoting 
effects of AKT under conditions of cellular stress (Yamaguchi 
and Wang, 2001; Gardai et al., 2004; Moriishi et al., 2014). 
Mutually, AKT-mediated phosphorylation of the BCL2 
protein abrogates its proapoptotic activity (Jendrossek, 2012; 
Szymonowicz et al., 2018). Thus, we hypothesized that the 
PIK3CG/AKT/BCL2 pathway is involved in the interventional 
regulation of APS in TNBC cells. We found that the expression 
of PIK3CG, p-AKT, and BCL2 was significantly decreased by 
increasing APS concentration.
These results also reversely indicate that IP, utilization of 
the interplay of network pharmacology, big data for disease 
molecules, and computer-aided simulation, is a convenient 
way to discover natural products with high efficiency and 
translation potential. At the same time, IP also provides a 
system-level approach to understanding multi-target treatment 
strategies for disease. This also helps to design new molecular 
frameworks based on intrinsic and extrinsic intervention 
mechanisms. Natural products have enormous structural 
diversity and various bioactivities, and the appropriate use 
of IP methods can initiate new directions and improve our 
overall understanding.
CONClUsION
In conclusion, by integrated pharmacological methods, we 
have identified APS as a key product that can interfere with the 
development of TNBC by disturbing the PIK3CG/AKT/BCL2 
pathway. This study further confirmed that APS can effectively 
inhibit the activity and invasion and enhance the apoptosis 
of MDA-MB-231 cells as well as exert a key inhibitory effect 
on the expression of PIK3CG, AKT, and BCL2. Obviously, 
comprehensive pharmacology is effective as a means of exploring 
natural products that interfere with cancer.
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